Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jian'er Qingjie is a Traditional Chinese Medicine (TCM) formulation primarily used in pediatric care for the treatment of acute upper respiratory tract infections (AURTI). Developed by the China National Pharmaceutical Industry Research Institute, it is typically administered as an oral liquid. The formulation consists of several herbal components, including *Lonicera japonica* (honeysuckle), *Chrysanthemum indicum*, *Forsythia suspensa*, *Crataegus pinnatifida* (hawthorn), *Citrus reticulata* (tangerine peel), and *Glycyrrhiza uralensis* (licorice). It is designed to clear heat, detoxify, and promote digestion. Its mechanism of action involves anti-inflammatory, antiviral, and antibacterial properties attributed to its phytochemical constituents like chlorogenic acid, luteolin, and phillyrin. It is commonly prescribed for symptoms such as fever, cough, sore throat, and loss of appetite associated with viral or bacterial infections in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jian'er Qingjie.